Cargando…
Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline
Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients ex...
Autores principales: | Minami, Sakiko, Nagai, Norihiro, Suzuki, Misa, Kurihara, Toshihide, Sonobe, Hideki, Kamoshita, Mamoru, Uchida, Atsuro, Shinoda, Hajime, Takagi, Hitoshi, Sonoda, Shozo, Sakamoto, Taiji, Tsubota, Kazuo, Ozawa, Yoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758719/ https://www.ncbi.nlm.nih.gov/pubmed/29311612 http://dx.doi.org/10.1038/s41598-017-18255-4 |
Ejemplares similares
-
Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment
por: Nagai, Norihiro, et al.
Publicado: (2016) -
Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy
por: Nagai, Norihiro, et al.
Publicado: (2019) -
QD laser eyewear as a visual field aid in a visual field defect model
por: Iyama, Chigusa, et al.
Publicado: (2019) -
Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice
por: Sato, Shinri, et al.
Publicado: (2017) -
Macular Pigment Optical Density and Photoreceptor Outer Segment Length as Predisease Biomarkers for Age-Related Macular Degeneration
por: Nagai, Norihiro, et al.
Publicado: (2020)